Condition: HIV-1 · SARS-CoV-2 · Sponsor: Assistance Publique - Hôpitaux de Paris
We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis.
This description comes directly from the study's public registry record.
Claude CAPRON, MD, PhD · + 33 01 49 09 58 47 · claude.capron@aphp.fr
Fernando REAL, PhD · + 33 03 20 87 12 01 · fernando.real@cnrs.fr
Always discuss trial participation with your own doctor first.
| Hematology and interne medicine department, Ambroise Paré hospital - APHP | Boulogne-Billancourt, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06458504